Progress in treatment of high-risk non-disabling ischemic cerebrovascular events
HUANG Huan1, 2, SU Weidong1, 2, TAN Hong2
Author information+
1. Department of Neurology, Changsha Hospital Affiliated to University of South China, Changsha 410005, Hunan Province, China; 2. Department of Neurology, First Hospital of Changsha, Changsha 410005, Hunan Province, China
The early and precise treatment of high-risk non-disabling ischemic cerebrovascular event (HR-NICE) has directly influenced on prognosis, and it attracts more attention. Although intravenous thrombolysis is generally acknowledged as the most effective therapy for ischemic stroke, but it is still in dispute for HR-NICE. This article reviews the domestic and abroad progress in HR-NICE in recent years.
HUANG Huan1, 2, SU Weidong1, 2, TAN Hong2. Progress in treatment of high-risk non-disabling ischemic cerebrovascular events[J]. Journal of Neurology and Neurorehabilitation. 2018, 14(1): 33-37 https://doi.org/10.12022/jnnr.2017-0075